PharmaTher Holdings Ltd (PHRM) AI Stock Analysis

• Market Cap: C$6.83M
• Dividend Yield: N/A
• Average Volume (3M): 158.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: N/A
• EPS Growth: 27.35%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 91,019,066
• 10 Day Avg. Volume: 117,358
• 30 Day Avg. Volume: 158,340
• PEG Ratio: 0.20
• Price to Book (P/B): 16.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.07 ▼(-28.00% Downside)
• Action: Reiterated Date: 02/10/26
• Date: Action: Reiterated 02/10/26

The score is primarily held down by weak financial performance (pre-revenue, ongoing losses, negative cash flow, and shrinking equity) and poor technicals (price below key moving averages with negative MACD). Improved loss/cash-burn trends and zero reported debt provide partial offset, while valuation is hard to assess meaningfully due to negative earnings and no dividend data.

Positive Factors

Low leverage / no debt

Zero reported debt materially reduces financial distress risk for a pre-revenue biotech. Without interest obligations the company has greater flexibility to allocate scarce cash to R&D or trials, improving strategic optionality and lowering near-term insolvency pressure relative to leveraged peers.

Improving loss and cash-burn trends

Sustained narrowing of net losses demonstrates improving cost discipline and operational execution. Lower burn rates extend runway, reduce near-term financing frequency, and indicate management can prioritize resources to advance clinical programs, a durable improvement supporting longer-term viability.

Focused specialty pipeline

A concentrated focus on ketamine-related therapies targets expanding, structural markets (mental health and pain). Specialization can create technical expertise, faster trial learning curves, and partnership/licensing appeal, improving commercialization prospects if clinical milestones are met.

Negative Factors

Pre-revenue business model

Lack of commercial revenue means the business is entirely dependent on R&D progress and future approvals to generate sustainable cash flow. This elevates execution and regulatory risk, elongates time to profitability, and makes long-term viability contingent on uncertain trial and approval outcomes.

Eroding shareholders' equity

Rapid depletion of equity reduces the balance-sheet cushion to absorb setbacks and limits borrowing capacity. A thin equity base increases the likelihood of dilutive capital raises, constrains strategic maneuvers, and raises bankruptcy risk if negative trends persist or unexpected costs emerge.

Negative operating cash flow; financing reliance

Persistent negative operating and free cash flow forces ongoing external funding needs. Even with improved burn, reliance on capital markets or financings creates dilution and execution risk, and access could be constrained by the small equity base and prior cumulative losses.

PharmaTher Holdings Ltd Business Overview & Revenue Model

Company Description

PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.

How the Company Makes Money

PharmaTher Holdings Ltd generates revenue primarily through the development and commercialization of its proprietary psychedelic-based therapies. The company's revenue model includes licensing agreements, partnerships, and collaborative research and development efforts with other pharmaceutical companies. These agreements often involve upfront payments, milestone payments, and royalties on sales of successful therapies. Additionally, PharmaTher may receive funding from grants and government programs that support research in psychedelic medicine. The company's focus on strategic collaborations and intellectual property development plays a critical role in its ability to generate revenue and sustain growth in the competitive biotech landscape.

PharmaTher Holdings Ltd Financial Statement Overview

Summary

Financial profile remains weak: the company is pre-revenue with ongoing net losses and negative operating/free cash flow (TTM FCF about -1.1M). Positives include no reported debt and meaningful improvement in losses and cash burn versus prior years, but equity has eroded sharply, raising ongoing funding risk.

Income Statement

The company is still pre-revenue (revenue is 0 across annual periods and TTM (Trailing-Twelve-Months)), and profitability remains negative with EBIT and net losses continuing in TTM (net loss of ~1.6M). A key positive is that losses have narrowed materially versus prior years (annual net loss improved from ~6.4M in 2023 and ~3.1M in 2024 to ~1.5M in 2025), suggesting improved cost control. However, the lack of commercial revenue and ongoing negative earnings keep the income statement weak and highly dependent on funding and future product/clinical progress.

Balance Sheet

Balance sheet leverage is low with total debt reported at 0 (debt-to-equity at 0), which reduces financial risk. The main concern is shrinking equity over time (from ~11.8M in 2022 to ~0.8M in TTM (Trailing-Twelve-Months)), reflecting cumulative losses and balance-sheet burn. Returns on equity are deeply negative, highlighting that current capital is not generating profits and leaving a thinner cushion if losses persist.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are negative in TTM (Trailing-Twelve-Months) (about -1.1M), consistent with an R&D-driven business model without revenue. Cash burn has improved versus 2024 (operating cash flow was about -3.5M), but free cash flow growth in TTM is sharply negative, indicating near-term volatility in cash usage. With ongoing negative cash flow, the company likely remains reliant on external financing despite the reduced burn rate.

Breakdown	Aug 2025	Aug 2024	Aug 2023	Aug 2022	Aug 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-711.00	-1.42K	-1.78K	-355.00
EBITDA	-1.52M	-3.04M	-3.96M	-3.96M	-2.43M
Net Income	-1.53M	-3.12M	-6.42M	-4.01M	2.66M
Balance Sheet
Total Assets	1.34M	2.59M	6.31M	12.16M	5.94M
Cash, Cash Equivalents and Short-Term Investments	1.12M	2.30M	6.25M	12.12M	5.88M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	366.33K	252.90K	892.48K	330.32K	361.06K
Stockholders Equity	973.54K	2.34M	5.42M	11.83M	5.58M
Cash Flow
Free Cash Flow	-1.21M	-3.52M	-3.24M	-3.51M	917.92K
Operating Cash Flow	-1.21M	-3.52M	-3.24M	-3.51M	922.19K
Investing Cash Flow	0.00	-300.00K	0.00	0.00	214.77K
Financing Cash Flow	0.00	35.00K	0.00	9.89M	1.25M

PharmaTher Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRM, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and below the 200-day MA of 0.24, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.51 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PHRM.

PharmaTher Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BETR	46 Neutral	C$9.11M	-4.51	―	―	―	62.43%
PHRM	42 Neutral	C$6.83M	-4.57	-112.32%	―	―	27.35%
MRVL	42 Neutral	C$7.83M	-3.00	―	―	―	―
KNE	41 Neutral	C$7.26M	-3.28	―	―	―	―
BIOV	29 Underperform	C$4.52M	-0.70	―	―	―	25.09%

PharmaTher Holdings Ltd Corporate Events

PharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market

PharmaTher Holdings Ltd. has launched a strategic initiative to seek Health Canada approval and subsequent commercialization of a generic version of semaglutide, the active ingredient in blockbuster diabetes and obesity drugs Ozempic and Wegovy, targeting Canada as one of the first major markets to open to regulated generic competition following the expiry of semaglutide’s regulatory exclusivity. Leveraging its past success in gaining FDA approval and monetizing U.S. rights to ketamine, the company aims to be among the early suppliers of generic semaglutide in Canada with broad dose coverage, a cost-effective sterile injectable manufacturing strategy, and a scalable platform to ensure reliable long-term supply and enable future global partnering opportunities in the fast-growing GLP-1 market.

The most recent analyst rating on (TSE:PHRM) stock is a Sell with a C$0.08 price target. To see the full list of analyst forecasts on PharmaTher Holdings Ltd stock, see the TSE:PHRM Stock Forecast page.

PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market

PharmaTher Holdings Ltd. announced a strategic expansion of its PharmaPatch microneedle patch platform into GLP-1 therapies aimed at treating obesity, building on preclinical progress and design know-how from its ketamine and psychedelic patch programs. The company plans to develop a needle-free, at-home, long-acting GLP-1 patch, potentially offering up to one month of sustained drug delivery, targeting a rapidly growing U.S. obesity treatment market projected to more than quadruple by 2030, and it is advancing feasibility, preclinical work and related patent protection to secure a differentiated position in this high-growth segment.

The most recent analyst rating on (TSE:PHRM) stock is a Sell with a C$0.10 price target. To see the full list of analyst forecasts on PharmaTher Holdings Ltd stock, see the TSE:PHRM Stock Forecast page.

PharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win

PharmaTher CEO Fabio Chianelli outlined how 2025 marked a transition from development to validation, highlighted by U.S. FDA approval of the company’s ketamine ANDA and its subsequent sale in a deal structured with upfront payments, milestones and profit-sharing that could exceed US$25 million. With reduced cash burn, a lean operating structure and expected receipts from the ketamine ANDA sale, PharmaTher says it is positioned to pursue 2026 goals without raising additional operating funds, focusing on international ketamine commercialization, strategic partnerships in Parkinson’s disease and drug delivery, monetization of its stake in Sairiyo Therapeutics, and development of next-generation and long-acting ketamine programs and platform tools such as KetaVault and KetAImine to accelerate asset monetization and strengthen its position as an asset-focused value creation company.

The most recent analyst rating on (TSE:PHRM) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on PharmaTher Holdings Ltd stock, see the TSE:PHRM Stock Forecast page.

PharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program

PharmaTher Holdings Ltd. has completed the sale of its Abbreviated New Drug Application for Ketamine Hydrochloride Injection USP, receiving an upfront cash payment and potential future milestone and profit-sharing payments. This move allows PharmaTher to concentrate on its long-acting injectable ketamine program, which aims to provide a more convenient and effective treatment option for neuropsychiatric disorders, potentially improving patient adherence and expanding market access.